Publications by authors named "Davide Busato"

Claim this Profile
G
Gut Microbiota-Based Immunotherapy: Engineered Nissle 1917 for Oral Delivery of Glypican-1 in Pancreatic Cancer.
Idris Vruzhaj, Marta Gambirasi, Davide Busato, Aurora Giacomin, Giuseppe Toffoli

Medicina (Kaunas)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Idarubicin-loaded chitosan nanobubbles to improve survival and decrease drug side effects in hepatocellular carcinoma.
Monica Mossenta, Monica Argenziano, Sara Capolla, Davide Busato, Paolo Durigutto

Nanomedicine (Lond)· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The anti-glypican 1 AT101 antibody as targeting agent to effectively deliver chitosan nanobubbles to glioblastoma cells.
Federica Di Cintio, Monica Argenziano, Anna Scomparin, Sara Capolla, Davide Busato

Nanomedicine (Lond)· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel complement-fixing IgM antibody targeting GPC1 as a useful immunotherapeutic strategy for the treatment of pancreatic ductal adenocarcinoma.
Davide Busato, Sara Capolla, Paolo Durigutto, Monica Mossenta, Sara Bozzer

J Transl Med· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted chitosan nanobubbles as a strategy to down-regulate microRNA-17 into B-cell lymphoma models.
Sara Capolla, Monica Argenziano, Sara Bozzer, Tiziana D'Agaro, Tamara Bittolo, Davide Busato

Front Immunol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies.
Monica Mossenta, Davide Busato, Michele Dal Bo, Paolo Macor, Giuseppe Toffoli

Int J Mol Sci· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal Adenocarcinoma.
Davide Busato, Monica Mossenta, Michele Dal Bo, Paolo Macor, Giuseppe Toffoli

Int J Mol Sci· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Epigenetic Machine Learning Model to Define Risk of Progression for Hepatocellular Carcinoma Patients.
Luca Bedon, Michele Dal Bo, Monica Mossenta, Davide Busato, Giuseppe Toffoli

Int J Mol Sci· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies.
Monica Mossenta, Davide Busato, Michele Dal Bo, Giuseppe Toffoli

Cancers (Basel)· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma.
Monica Mossenta, Davide Busato, Lorena Baboci, Federica Di Cintio, Giuseppe Toffoli

Cancers (Basel)· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel immunotherapeutic approaches for hepatocellular carcinoma treatment.
Davide Busato, Monica Mossenta, Lorena Baboci, Federica Di Cintio, Giuseppe Toffoli

Expert Rev Clin Pharmacol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis